These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 28594426)

  • 1. New developments in anticoagulants: Past, present and future.
    Weitz JI; Harenberg J
    Thromb Haemost; 2017 Jun; 117(7):1283-1288. PubMed ID: 28594426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticoagulation therapy in 2015: where we are and where we are going.
    Weitz JI
    J Thromb Thrombolysis; 2015 Apr; 39(3):264-72. PubMed ID: 25698404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-vitamin K oral anticoagulants versus vitamin K antagonists in the treatment of venous thromboembolic disease.
    Voukalis C; Lip GY; Shantsila E
    Expert Opin Pharmacother; 2016 Oct; 17(15):2033-47. PubMed ID: 27667112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pros and cons of new oral anticoagulants.
    Bauer KA
    Hematology Am Soc Hematol Educ Program; 2013; 2013():464-70. PubMed ID: 24319220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute phase treatment of VTE: Anticoagulation, including non-vitamin K antagonist oral anticoagulants.
    Hillis C; Crowther MA
    Thromb Haemost; 2015 Jun; 113(6):1193-202. PubMed ID: 25948149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-vitamin K antagonist oral anticoagulants (NOACs): clinical evidence and therapeutic considerations.
    Saraf K; Morris PD; Garg P; Sheridan P; Storey R
    Postgrad Med J; 2014 Sep; 90(1067):520-8. PubMed ID: 25085900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of direct oral anticoagulants for the treatment of cancer-associated thrombosis: an update.
    Franco-Moreno A; Cabezón-Gutiérrez L; Palka-Kotlowsa M; Villamayor-Delgado M; García-Navarro M
    J Thromb Thrombolysis; 2019 Apr; 47(3):409-419. PubMed ID: 30467760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
    Beyer-Westendorf J; Ageno W
    Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal of anticoagulants: an overview of current developments.
    Greinacher A; Thiele T; Selleng K
    Thromb Haemost; 2015 May; 113(5):931-42. PubMed ID: 25832311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venous thromboembolism management: where do novel anticoagulants fit?
    Spyropoulos AC; Turpie AG
    Curr Med Res Opin; 2013 Jul; 29(7):783-90. PubMed ID: 23659584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: a review of the literature.
    Becattini C; Vedovati MC; Agnelli G
    Thromb Res; 2012 Mar; 129(3):392-400. PubMed ID: 22264937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factor XI and factor XII as targets for new anticoagulants.
    Weitz JI
    Thromb Res; 2016 May; 141 Suppl 2():S40-5. PubMed ID: 27207423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonvitamin K antagonist oral anticoagulants in everyday practice: Stroke prevention in atrial fibrillation and treatment of venous thromboembolism.
    Bentz BA
    J Am Assoc Nurse Pract; 2015 Dec; 27(12):721-31. PubMed ID: 26676209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life.
    Giustozzi M; Vedovati MC; Verdecchia P; Pierpaoli L; Verso M; Conti S; Cianella F; Marchesini E; Filippucci E; Agnelli G; Becattini C
    Eur J Intern Med; 2016 Sep; 33():42-6. PubMed ID: 27394924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?
    Laux V; Perzborn E; Heitmeier S; von Degenfeld G; Dittrich-Wengenroth E; Buchmüller A; Gerdes C; Misselwitz F
    Thromb Haemost; 2009 Nov; 102(5):892-9. PubMed ID: 19888525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The discovery of dabigatran etexilate for the treatment of venous thrombosis.
    Feuring M; van Ryn J
    Expert Opin Drug Discov; 2016 Jul; 11(7):717-31. PubMed ID: 27159158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events.
    Mekaj YH; Mekaj AY; Duci SB; Miftari EI
    Ther Clin Risk Manag; 2015; 11():967-77. PubMed ID: 26150723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The non-vitamin K antagonist oral anticoagulants and heparin-induced prolongation of the activated coagulation time.
    Negro F; Caravelli P; Morganti R; Casini M; Ruocco L; Tripodi A; De Caterina R
    Vascul Pharmacol; 2022 Jun; 144():106994. PubMed ID: 35436607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticoagulation in children: Making the most of little patients and little evidence.
    Young G; Male C; van Ommen CH
    Blood Cells Mol Dis; 2017 Sep; 67():48-53. PubMed ID: 28552476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative efficacy and safety of the non-vitamin K antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation.
    Senoo K; Lip GY
    Semin Thromb Hemost; 2015 Mar; 41(2):146-53. PubMed ID: 25682085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.